High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
3 Analyst Rating
Wall Street analysts forecast NEUP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEUP is 14.43 USD with a low forecast of 2.30 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.270
Low
2.30
Averages
14.43
High
21.00
Current: 4.270
Low
2.30
Averages
14.43
High
21.00
Lucid Capital
Elemer Piros
Buy -> Neutral
downgrade
$81
2025-10-21
Reason
Lucid Capital
Elemer Piros
Price Target
$81
2025-10-21
downgrade
Buy -> Neutral
Reason
Lucid Capital analyst Elemer Piros downgraded Neuphoria Therapeutics to Neutral from Buy with a price target of $2.30, down from $81, after the Phase 3 AFFIRM-1 trial of BNC210 for the acute treatment of social anxiety disorder failed to meet its primary endpoint. The study also did not show statistically significant results across secondary endpoints, the analyst tells investors in a research note.
Maxim
Maxim
Buy
maintain
$18 -> $35
2025-09-11
Reason
Maxim
Maxim
Price Target
$18 -> $35
2025-09-11
maintain
Buy
Reason
Maxim raised the firm's price target on Neuphoria Therapeutics to $35 from $18 and keeps a Buy rating on the shares. The firm cites the company's announcement that enrollment has been completed in the Phase 3 'AFFIRM-1' study of BNC210 in social anxiety disorder, positioning for a top-line data readout in early Q4, the analyst tells investors in a research note. Maxim adds that it continues to believe the risk/reward is favorable and as such, lowers the discount rate in its valuation model to 30% from 35%, which raises its price target.
Lucid Capital
NULL
to
Buy
initiated
$81
2025-09-04
Reason
Lucid Capital
Price Target
$81
2025-09-04
initiated
NULL
to
Buy
Reason
Lucid Capital initiated coverage of Neuphoria Therapeutics with a Buy rating and $81 price target. The company is developing BNC210 to treat social anxiety disorder episodically, the analyst tells investors in a research note. The firm says that with no agent approved for the acute treatment of anxiety attacks in a social situation, BNC210 offers a "best- and first-in-class" profile.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Neuphoria Therapeutics Inc (NEUP.O) is -0.69, compared to its 5-year average forward P/E of -1.78. For a more detailed relative valuation and DCF analysis to assess Neuphoria Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.78
Current PE
-0.69
Overvalued PE
-0.58
Undervalued PE
-2.97
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.12
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.18
Undervalued EV/EBITDA
-0.42
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.37
Current PS
0.00
Overvalued PS
1.40
Undervalued PS
-0.66
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Gross Profit Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
NEUP News & Events
Events Timeline
(ET)
2025-12-04
08:10:00
Neuphoria Therapeutics Evaluates Lynx1 Acquisition Proposal
2025-12-01 (ET)
2025-12-01
08:10:00
Neuphoria Therapeutics Counteracts Lynx1 Fund's Deceptive Claims
2025-11-11 (ET)
2025-11-11
07:03:10
Neuphoria begins strategic evaluation, acknowledges receipt of interest indication.
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/7711f3f31cffe49676ed64ab06513ee48e22cdbe592a760a767f8f14dee6e800.png)
Preview
4.5
10-24BenzingaNasdaq Rises 1%; Procter & Gamble Reports Positive Earnings
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/tipranks.png)
Preview
4.5
10-22TipRanksTuesday's Major Stock Market Highlights: Morning News Summary!
Preview
9.0
10-21TipRanksWhat Caused Neuphoria Therapeutics Stock (NEUP) to Drop 65% Today?
Sign Up For More News
People Also Watch
FAQ
What is Neuphoria Therapeutics Inc (NEUP) stock price today?
What is Neuphoria Therapeutics Inc (NEUP)'s business?
What is the price predicton of NEUP Stock?
What is Neuphoria Therapeutics Inc (NEUP)'s revenue for the last quarter?
What is Neuphoria Therapeutics Inc (NEUP)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Neuphoria Therapeutics Inc (NEUP)'s fundamentals?
How many employees does Neuphoria Therapeutics Inc (NEUP). have?